Sunday, May 29, 2022
No Result
View All Result
Medical Finance
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
No Result
View All Result
Medical Finance
No Result
View All Result
Home Coronavirus

Third dose of COVID mRNA vaccine safe and effective in kidney transplant patients

by Medical Finance
in Coronavirus
Study: Humoral Response to The Third Dose Of SARS-Cov-2 Vaccine in Kidney Transplant Recipients. Image Credit: bluebay / Shutterstock.com
9
SHARES
99
VIEWS
Share on FacebookShare on Twitter

Immunocompromised patients are at a high risk of severe coronavirus disease 2019 (COVID-19) and also respond poorly to vaccination with available COVID-19 vaccines.

An interesting new Transplantation Proceedings study reports that a third dose of the Pfizer messenger ribonucleic acid (mRNA) BNT162b2 vaccine produces high levels of anti-spike immunoglobulin G (IgG) antibodies, even when the individual has failed to show evidence of seroconversion after two doses.

Study: Humoral Response to The Third Dose Of SARS-Cov-2 Vaccine in Kidney Transplant Recipients. Image Credit: bluebay / Shutterstock.com

Study: Humoral Response to The Third Dose Of SARS-Cov-2 Vaccine in Kidney Transplant Recipients. Image Credit: bluebay / Shutterstock.com

Introduction

Solid-organ transplant (SOT) patients are at a high risk of severe or fatal illness due to COVID-19 and have been prioritized for vaccination. However, most of these patients do not respond adequately to COVID-19 vaccines, even after two doses, with low levels of humoral and cellular immune responses.

To counter this, a third dose was recommended for these patients. This has been reported to produce an immune boost without obvious acute or serious adverse effects when given within three months of the second dose.

The current study assesses the antibody response to the third dose of the Pfizer vaccine when given six months from the second dose in a kidney transplant patient population. The scientists also looked at the baseline distribution of the cellular immune response among these recipients as compared to healthy controls.

Study findings

A total of 130 kidney transplant recipients (KTR) who had received transplants between January 1, 1996, and May 1, 2021, were included in the current study. Less than 10% of these study participants had multiple transplants.

While 16 had received two doses of the vaccine prior to transplantation, the others received it afterward. All individuals received the third dose after transplantation.

All transplants occurred three or more months before vaccination. The third booster dose was not associated with any safety events, including acute rejections, allergic reactions, or neurological events over the next 1.5 months.

60% of KTR did not seroconvert, as shown by tests taken immediately before the third dose. The median anti-spike IgG levels in this group were 35 AU/mL as compared to 687 AU/mL in the control group. This was due to the large proportion of seronegative samples, with the median among the seropositive KTR alone being about 190 AU/mL as compared to 709 AU/mL among seropositive controls.

Of the 78 seronegative KTR, 47 (60%) seroconverted after the third dose and developed significant levels of anti-spike IgG. This led to a 76% rate of seroconversion with three doses as compared to 40% after two.

After the third dose, antibody titers rose to a median of about 1,300 and 28,000 in the study participants and controls, respectively. Thus, the immune response was an order of magnitude higher in immunocompetent controls.

The primary risk factors for a poor immune response included increasing age, which was associated with a 5% higher risk of seroconversion failure per year, low baseline antibody titers before the third dose, and lymphopenia. Younger patients were more likely to benefit from the third dose with a higher rise in antibody titers, while those above 60 years showed a markedly lower humoral response.  

Functional CD4 T-cells were significantly higher by mean percentage, as evaluated by the expression of tumor necrosis factor (TNF)-α and interferon (IFN)-γ. TNF-α levels were also associated with the average increase in antibody titers after the third booster dose. Interestingly, neither KTR nor controls showed a significant CD8 T-cell response.

Implications

Earlier research has shown that antibody- and cell-mediated immunity to the COVID-19 vaccines is reduced in KTR. In the current study, a third booster dose of the Pfizer mRNA vaccine immediately led the greater antibody titers as compared to those before the third dose.

Notably, a 40% seroconversion rate was reported after two doses, which was comparable to 97% of controls; however, the seroconversion rate in KTR rose to 76% by a third booster dose. This is supported by recent research which shows that as immunity wanes over time, breakthrough infections become more common.

Despite this, and even though the third dose did not raise the antibody levels anywhere near those achieved by immunocompetent controls, cell-mediated immunity led to a better outcome.

The study also confirmed the poor antibody response with advancing age, regardless of whether the individual was exposed to the virus through natural infection or through vaccination. Unlike other studies, the extent of immunosuppression was not linked to the seropositivity rates, perhaps because “the lower titer of antibody before the booster has a strong statistical significancy which overcome other clinical parameters related to it.”

A third dose of BNT162b2 mRNA vaccine in kidney recipients is safe, and effectively results in increased IgG anti-S levels, including in individuals who were seronegative after two doses.”

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Medical Finance

Medical Finance

Related Posts

Study: Long-Term Persistence of IgG Antibodies in recovered COVID-19 individuals at 18 months and the impact of two-dose BNT162b2 (Pfizer-BioNTech) mRNA vaccination on the antibody response. Image Credit: Kateryna Kon/Shutterstock

Antibody response 18 months after SARS-CoV-2 infection in vaccinated and unvaccinated individuals

by Medical Finance
May 29, 2022
0

Several severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants have emerged since the coronavirus disease 2019 (COVID-19) pandemic. These...

Study: Selection analysis identifies unusual clustered mutational changes in Omicron lineage BA.1 that likely impact Spike function. Image Credit: Naeblys/Shutterstock

Impact of clustered mutations in SARS-CoV-2 Omicron spike function

by Medical Finance
May 29, 2022
0

In a recent study posted to the bioRxiv* preprint server, researchers explored the characteristics of severe acute respiratory syndrome coronavirus...

Study: The impact of recurrent rapid test strategies on the effectiveness of at-home antiviral treatments for SARS-CoV-2. Image Credit: Cryptographer/Shutterstock

Researchers examine benefits of lateral flow testing with regards to the new Paxlovid drug for treatment of COVID-19

by Medical Finance
May 29, 2022
0

Lateral flow devices, or lateral flow tests, have played a significant role in helping to identify infectious individuals during the...

Study: Obesity associated with attenuated tissue immune cell responses in COVID-19. Image Credit: Eve Orea/Shutterstock

Attenuated tissue immune responses against SARS-CoV-2 in obese and non-obese patients

by Medical Finance
May 29, 2022
0

In a recent study posted to the bioRxiv* preprint server, researchers analyzed the lung and peripheral blood immune responses associated with...

Study: “Never let a good crisis go to waste”: Positives from disrupted maternity care in Australia during COVID-19. Image Credit: Prostock-studio/Shutterstock

Positive effects of altered maternal care during COVID-19 in Australia

by Medical Finance
May 29, 2022
0

In a recent study published in Midwifery, researchers reported on the positive outcomes of the coronavirus disease 2019 (COVID-19) pandemic...

Study: Booster vaccination to curtail COVID-19 resurgence - population-level implications of the Israeli campaign. Image Credit: Corona Borealis Studio/Shutterstock

Impact of SARS-CoV-2 booster vaccination on Delta variant resurgence in Israel

by Medical Finance
May 29, 2022
0

In a recent study posted to the medRxiv* preprint server, researchers explored the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)...

Next Post
Study: Long-Term Persistence of IgG Antibodies in recovered COVID-19 individuals at 18 months and the impact of two-dose BNT162b2 (Pfizer-BioNTech) mRNA vaccination on the antibody response. Image Credit: Kateryna Kon/Shutterstock

Antibody response 18 months after SARS-CoV-2 infection in vaccinated and unvaccinated individuals

Study: Selection analysis identifies unusual clustered mutational changes in Omicron lineage BA.1 that likely impact Spike function. Image Credit: Naeblys/Shutterstock

Impact of clustered mutations in SARS-CoV-2 Omicron spike function

0 0 votes
Article Rating
Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Support

  • Contact
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms And Conditions

Categories

  • Coronavirus
  • Insights From Industry
  • Interviews
  • Mediknowledge
  • News
  • Thought Leaders
  • Whitepapers

More News

  • By Juan Gaertner 2e3ffe20f38f40049d48d5240ee9a735 620x480
    Mayo Clinic researchers report differences in genomic data quality among racial groups
  • Study: Structural dynamics of SARS-CoV-2 nucleocapsid protein induced by RNA binding. Image Credit: Naeblys / Shutterstock.com
    RNA binding-induced structural dynamics of SARS-CoV-2 nucleocapsid protein
  • Home
  • Privacy Policy
  • Contact
  • Disclaimer
  • Terms And Conditions

© 2022 Medical Finance - Latest Financial and Business News

No Result
View All Result
  • Interviews
  • Mediknowledge
  • News
  • Insights From Industry
  • Coronavirus
  • Thought Leaders
  • Whitepapers
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply